• Martina Kovac, Himal Lal, Anthony L Cunningham, Myron J Levin, Robert W Johnson, Laura Campora, Antonio Volpi, Thomas C Heineman, and ZOE-50/70 Study Group.
• GSK, Rockville, MD, USA. Electronic address: martina.z.kovac@gsk.com.
• Vaccine. 2018 Mar 14; 36 (12): 1537-1541.

BackgroundAn adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged ≥50 and ≥70 years (ZOE-50 and ZOE-70, respectively).MethodsData from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases.ResultsIn the pooled ZOE-50/ZOE-70 analysis, 1 of 32 HZ/su recipients (3.1%) and 16 of 477 placebo recipients (3.4%) with a confirmed HZ episode had complications other than PHN. Efficacy against HZ-related complications was 93.7% (95% confidence interval, 59.5-99.9%) in adults aged ≥50 years and 91.6% (43.3-99.8%) in adults ≥70 years. Five HZ-related hospitalizations, all in placebo recipients, and no HZ-related deaths were reported.ConclusionsHZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177; NCT01165229).Copyright © 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.

36 keywords...

hide…